aTyr Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference
04 janv. 2018 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma to Participate at the Piper Jaffray 29th Annual Healthcare Conference
21 nov. 2017 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 21, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat...
aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update
14 nov. 2017 16h05 HE
|
aTyr Pharma, Inc.
- Initiation of Phase 1 clinical trial of iMod.Fc on-track for this quarter - - Selection of antibody for ORCA program on-track for this quarter - SAN DIEGO, Nov. 14, 2017 (GLOBE NEWSWIRE) -- aTyr...
aTyr Pharma Announces Leadership Transition
01 nov. 2017 16h05 HE
|
aTyr Pharma, Inc.
– Dr. John Mendlein Transitions from CEO to Non-Executive Board Member,Dr. Sanjay Shukla Appointed President and CEO – SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE),...